RT Journal Article
SR Electronic
T1 Development and validation of an early warning score (EWAS) for predicting clinical deterioration in patients with coronavirus disease 2019
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.04.17.20064691
DO 10.1101/2020.04.17.20064691
A1 Guo, Yabing
A1 Liu, Yingxia
A1 Lu, Jiatao
A1 Fan, Rong
A1 Zhang, Fuchun
A1 Yin, Xueru
A1 Liu, Zhihong
A1 Zeng, Qinglang
A1 Yuan, Jing
A1 Hu, Shufang
A1 Wang, Qiongya
A1 Liao, Baolin
A1 Huang, Mingxing
A1 Yin, Sichun
A1 Zhang, Xilin
A1 Xin, Rui
A1 Lin, Zhanzhou
A1 Hu, Changzheng
A1 Zhao, Boliang
A1 He, Ridong
A1 Liang, Minfeng
A1 Zhang, Zheng
A1 Liu, Li
A1 Sun, Jian
A1 Tang, Lu
A1 Deng, Lisi
A1 Xia, Jinyu
A1 Tang, Xiaoping
A1 Liu, Lei
A1 Hou, Jinlin
A1 ,
YR 2020
UL http://medrxiv.org/content/early/2020/04/21/2020.04.17.20064691.abstract
AB Background Since the pandemic outbreak of coronavirus disease 2019 (COVID-19), the health system capacity in highly endemic areas has been overwhelmed. Approaches to efficient management are urgently needed. We aimed to develop and validate a score for early prediction of clinical deterioration of COVID-19 patients.Methods In this retrospective multicenter cohort study, we included 1138 mild to moderate COVID-19 patients admitted to 33 hospitals in Guangdong Province from December 27, 2019 to March 4, 2020 (N =818; training cohort), as well as two hospitals in Hubei Province from January 21 to February 22, 2020 (N =320; validation cohort) in the analysis.Results The 14-day cumulative incidences of clinical deterioration were 7.9% and 12.1% in the training and validation cohorts, respectively. An Early WArning Score (EWAS) (ranging from 0 to 4.5), comprising of age, underlying chronic disease, neutrophil to lymphocyte ratio, C-reactive protein, and D-dimer levels, was developed (AUROC: 0.857). By applying the EWAS, patients were categorized into low-, medium-, and high risk groups (cut-off values: two and three). The 14-day cumulative incidence of clinical deterioration in the low-risk group was 1.8%, which was significantly lower than the incidence rates in the medium-(14.4%) and high-risk (40.9%) groups (P <.001). The predictability of EWAS was similar in the validation cohort (AUROC =0.781), patients in the low-, medium-, and high-risk groups had 14-day cumulative incidences of 2.6%, 10.0%, and 25.7%, respectively (P <.001).Conclusion The EWAS, which is based on five common parameters, can predict COVID-19-related clinical deterioration and may be a useful tool for a rapid triage and establishing a COVID-19 hierarchical management system that will greatly focus clinical management and medical resources to reduce mortality in highly endemic areas.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNAFunding StatementThis study was funded by the Local Innovative and Research Teams Project of Guangdong Pearl River Talents Program (2017BT01S131).Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data included were available.